Celcuity, Inc. (NASDAQ:CELC) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Posted by Brian Himes on Jun 4th, 2026

Shares of Celcuity, Inc. (NASDAQ:CELC – Get Free Report) have earned an average rating of “Moderate Buy” from the twelve ratings firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and eleven have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $152.0909.

CELC has been the subject of a number of research analyst reports. Citigroup reiterated a “market outperform” rating on shares of Celcuity in a research report on Thursday, May 28th. Wells Fargo & Company cut their target price on shares of Celcuity from $183.00 to $166.00 and set an “overweight” rating for the company in a research report on Wednesday. Leerink Partners set a $155.00 target price on shares of Celcuity in a research report on Tuesday. Stifel Nicolaus set a $150.00 price target on shares of Celcuity in a research note on Monday, May 4th. Finally, Craig Hallum dropped their price target on shares of Celcuity from $189.00 to $171.00 and set a “buy” rating on the stock in a research note on Wednesday.

Get Our Latest Stock Analysis on CELC

Insider Buying and Selling at Celcuity

In other news, Director David Dalvey sold 25,000 shares of the stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the transaction, the director owned 65,000 shares in the company, valued at $9,144,200. This represents a 27.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the transaction, the director owned 6,760 shares in the company, valued at approximately $949,509.60. This trade represents a 57.11% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 37,000 shares of company stock worth $5,111,950. 13.33% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Parallel Advisors LLC acquired a new position in shares of Celcuity during the 1st quarter worth $38,000. EverSource Wealth Advisors LLC increased its stake in shares of Celcuity by 1,329.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after purchasing an additional 319 shares during the last quarter. Meeder Asset Management Inc. acquired a new position in shares of Celcuity during the 4th quarter worth $42,000. PNC Financial Services Group Inc. increased its stake in shares of Celcuity by 20.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 514 shares of the company’s stock worth $59,000 after purchasing an additional 86 shares during the last quarter. Finally, Ogorek Anthony Joseph NY ADV acquired a new position in shares of Celcuity during the 3rd quarter worth $27,000. Institutional investors and hedge funds own 63.33% of the company’s stock.

Trending Headlines about Celcuity

Here are the key news stories impacting Celcuity this week:

Positive Sentiment: Several analysts and commentary pieces said the selloff may be overdone, noting that gedatolisib still showed strong progression-free survival and response-rate benefits and could support blockbuster potential in a multi-billion-dollar breast cancer market. Celcuity: Selloff On Yesterday’s Data Unwarranted – Buy Rating Upheld
Positive Sentiment: HC Wainwright lowered its price target to $145 from $185 but kept a buy rating, implying substantial upside from current levels. HC Wainwright rating update via Benzinga/The Fly
Positive Sentiment: Management said FDA approval is expected by July 2026 for one breast-cancer subgroup, with an additional filing planned for the mutant cohort, keeping the regulatory catalyst in focus. Convertible notes offering announcement
Neutral Sentiment: Celcuity announced a proposed $400 million offering of convertible senior notes due 2032, which strengthens financing capacity but also raises potential dilution and capital structure concerns. Celcuity convertible senior notes offering
Negative Sentiment: Initial reaction to the Phase 3 readout was negative because investors judged the results against lofty expectations, with several reports saying the breast-cancer data “disappointed” despite remaining competitive. Reuters article on Celcuity plunge

Celcuity Trading Down 2.7%

Celcuity stock opened at $88.95 on Friday. The company has a debt-to-equity ratio of 6.04, a current ratio of 12.31 and a quick ratio of 12.31. The stock has a market capitalization of $4.34 billion, a PE ratio of -22.81 and a beta of 0.10. Celcuity has a 12-month low of $11.27 and a 12-month high of $151.02. The firm has a 50 day simple moving average of $122.64 and a 200-day simple moving average of $111.55.

Celcuity (NASDAQ:CELC – Get Free Report) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.10. As a group, equities research analysts expect that Celcuity will post -3.96 EPS for the current fiscal year.

Celcuity Company Profile

(Get Free Report)

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.